Maxwell Biosciences

Maxwell Biosciences is pioneering a 'Biomimetic Immune System' using its Claromer® platform to develop stable, broad-spectrum anti-infective drugs. Its lead candidate, MXB-22,510, has shown preclinical efficacy against a wide range of drug-resistant bacteria, fungi, and viruses, including pan-coronavirus and influenza. Founded in 2016 with roots in U.S. government-funded research, the company is preparing for human trials in 2026 and aims to provide a universal therapeutic solution for biodefense and age-related infectious disease.

Claromer® platform: AI-driven design of peptidomimetic small molecules (peptoids/N-substituted glycine oligomers) that mimic innate immune peptides (e.g., Cathelicidin LL-37) for broad-spectrum, pathogen-agnostic activity against bacteria, fungi, and viruses.

Competes with developers of novel antibiotic classes (e.g., synthetic biologists, phage therapy), broad-spectrum antivirals, and other peptide/peptidomimetic platforms. Its key differentiator is the claimed ultra-broad spectrum covering all three pathogen kingdoms (bacteria, fungi, viruses) with a single, stable, small-molecule approach.